SRGA · Surgalign Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $81.98M | $90.50M | $101.75M | $308.38M | $280.36M | - |
| Cost of Revenue | $41.69M | $29.77M | $44.00M | $137.26M | $142.66M | - |
| Gross Profit | $40.29M | $60.73M | $57.75M | $171.13M | $133.33M | - |
| R&D | $15.74M | $13.89M | $11.95M | $16.84M | $16.30M | - |
| SG&A | $95.89M | $124.42M | $124.39M | $157.68M | $116.67M | - |
| Total Operating Expenses | $119.65M | $201.94M | $255.77M | $352.98M | $148.58M | - |
| D&A | $2.18M | $2.48M | $6.58M | $22.68M | $16.53M | - |
| Operating Income | ($78.46M) | ($137.28M) | ($198.02M) | ($181.86M) | ($15.26M) | - |
| Interest Expense | $0 | - | - | $12.57M | $1.66M | - |
| Income Tax | ($1.04M) | ($886.0K) | ($3.49M) | $17.24M | ($3.23M) | - |
| Net Income | ($54.60M) | ($84.65M) | ($33.78M) | ($211.64M) | ($13.80M) | ($44.40M) |
| EPS - Basic | ($8.33) | ($0.69) | ($0.45) | ($2.91) | ($0.30) | - |
| EPS - Diluted | ($8.33) | ($0.69) | ($0.45) | ($2.91) | ($0.30) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $16.30M | $51.29M | $43.96M | $5.61M | $11.73M | - |
| Accounts Receivable | $16.06M | $19.20M | $27.09M | $59.29M | $38.57M | - |
| Inventory | $17.71M | $26.20M | $22.84M | $124.15M | $124.36M | - |
| Accounts Payable | $7.71M | $10.20M | $13.42M | $30.13M | $25.76M | - |
| Current Assets | $56.71M | $105.67M | $104.18M | $195.81M | $187.82M | - |
| Total Assets | $70.24M | $123.80M | $122.70M | $344.51M | $378.84M | - |
| Current Liabilities | $21.15M | $54.04M | $46.82M | $240.39M | $56.75M | - |
| Long-term Debt | $10.61M | $10.61M | - | - | - | - |
| Total Liabilities | $85.97M | $105.56M | $98.53M | $243.53M | $139.63M | - |
| Stockholders' Equity | ($25.73M) | $8.24M | $24.17M | $34.56M | $179.91M | - |
| Retained Earnings | ($624.22M) | ($569.61M) | ($484.96M) | ($451.18M) | ($228.25M) | - |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($52.11M) | ($51.79M) | ($88.04M) | ($9.46M) | $15.32M | - |
| Investing Cash Flow | ($7.26M) | ($24.83M) | $390.94M | ($116.13M) | ($17.95M) | - |
| Financing Cash Flow | $24.66M | $82.56M | ($263.04M) | $120.30M | $3.66M | - |
| CapEx | $6.78M | $13.42M | $10.12M | $14.43M | $12.30M | - |
| Free Cash Flow | ($58.89M) | ($65.22M) | ($98.15M) | ($23.88M) | $3.02M | - |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 49.1% | 67.1% | 56.8% | 55.5% | 47.6% | - |
| Operating margin | -95.7% | -151.7% | -194.6% | -59.0% | -5.4% | - |
| EBITDA margin | -93.0% | -149.0% | -188.1% | -51.6% | 0.5% | - |
| Net margin | -66.6% | -93.5% | -33.2% | -68.6% | -4.9% | - |
| Free cash flow margin | -71.8% | -72.1% | -96.5% | -7.7% | 1.1% | - |
| FCF / Net income | 1.08 | 0.77 | 2.91 | 0.11 | -0.22 | - |
| R&D / Revenue | 19.2% | 15.3% | 11.7% | 5.5% | 5.8% | - |
| SG&A / Revenue | 117.0% | 137.5% | 122.3% | 51.1% | 41.6% | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -77.7% | -68.4% | -27.5% | -61.4% | -3.6% | - |
| Return on equity | 212.2% | -1027.7% | -139.8% | -612.3% | -7.7% | - |
| Return on invested capital | - | -575.4% | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.68 | 1.96 | 2.23 | 0.81 | 3.31 | - |
| Quick ratio | 1.84 | 1.47 | 1.74 | 0.30 | 1.12 | - |
| Cash ratio | 0.77 | 0.95 | 0.94 | 0.02 | 0.21 | - |
| Leverage | ||||||
| Debt / Equity | -0.41 | 1.29 | - | - | - | - |
| Debt / Assets | 0.15 | 0.09 | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | -14.5x | -9.2x | - |
| Equity multiplier | -2.73 | 15.03 | 5.08 | 9.97 | 2.11 | - |
| Liabilities / Assets | 1.22 | 0.85 | 0.80 | 0.71 | 0.37 | - |
| Efficiency | ||||||
| Asset turnover | 1.17 | 0.73 | 0.83 | 0.90 | 0.74 | - |
| Inventory turnover | 2.35 | 1.14 | 1.93 | 1.11 | 1.15 | - |
| Days sales outstanding | 71d | 77d | 97d | 70d | 50d | - |
| Days inventory outstanding | 155d | 321d | 189d | 330d | 318d | - |
| Days payable outstanding | 67d | 125d | 111d | 80d | 66d | - |
| Cash conversion cycle | 159d | 274d | 175d | 320d | 303d | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -9.4% | -11.1% | -67.0% | 10.0% | - | - |
| Revenue CAGR (3y) | -35.7% | -31.4% | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -33.7% | 5.2% | -66.3% | 28.3% | - | - |
| Operating income growth (YoY) | 42.8% | 30.7% | -8.9% | -1092.0% | - | - |
| Net income growth (YoY) | 35.5% | -150.6% | 84.0% | -1433.1% | 68.9% | - |
| EPS growth (YoY) | -1107.2% | -53.3% | 84.5% | -870.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 9.7% | 33.6% | -311.0% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | - | -65.9% | -30.1% | -80.8% | - | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Geographic
$90.50M totalUS$77.93M · 86.1%
Non Us$12.57M · 13.9%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
-9.60
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Orthopedic, Prosthetic & Surgical Appliances & Supplies
Comparing SURGALIGN HOLDINGS against the 5 most active filers in the same SIC group.